The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
TERRAIN: A randomized, double-blind, phase II study comparing MDV3100 with bicalutamide (Bic) in men with metastatic castrate-resistant prostate cancer (CRPC).
Edwina S. Baskin-Bey
Employment or Leadership Position - Astellas Pharma
Neal D. Shore
Consultant or Advisory Role - Medivation/Astellas Pharma
Kenya Barber
Employment or Leadership Position - Astellas Pharma
Taoufik Ouatas
Employment or Leadership Position - Astellas Pharma (U)
Research Funding - Astellas Pharma
Axel Heidenreich
Consultant or Advisory Role - Astellas Pharma; Ipsen; Janssen-Cilag; Sanofi ; Takeda
Honoraria - Amgen; Astellas Pharma; Bayer; GlaxoSmithKline; Ipsen; Janssen-Cilag; Pfizer; Sanofi ; Takeda